The AMP platform
Harnessing the untapped potential of the lymph nodes for immunotherapy
- Elicio’s AMP platform technology is founded upon an intimate appreciation of the lymphatic system’s critical involvement in the functioning of the human immune system.
- Elicio believes the therapeutic utility of currently approved immunotherapies is limited due to the inability of those therapies to adequately engage with the critical immune cells resident in the lymph nodes responsible for priming T cell activation.
- The AMP platform is specifically intended to remedy this issue and the majority of Elicio’s product candidate portfolio, including its lead clinical candidate ELI-002, has been constructed upon this central tenet.